Drugs /

peginterferon alfa-2a

Back to Drugs List

Overview

NCI Definition [1]:
A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)

Clinical Trials

View Clinical Trials for peginterferon alfa-2a

Peginterferon alfa-2a has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating peginterferon alfa-2a, 1 is phase 1 (0 open) and 1 is phase 3 (0 open).

JAK2 V617F is the most frequent biomarker inclusion criterion for peginterferon alfa-2a clinical trials.

Essential thrombocythemia, malignant solid tumor, and mycosis fungoides are the most common diseases being investigated in peginterferon alfa-2a clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Peginterferon Alfa-2a
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating peginterferon alfa-2a and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
peg-interferon alpha-2a, polyethylene glycol-interferon alfa-2a, pegasys, peg-interferon alfa-2a, peginterferon alfa-2a, peg-interferon alfa-2a, polyethylene glycol-interferon alfa-2a, peg-ifna2a, peg-interferon alfa-2a, peginterferon alfa-2a (product), polyethylene glycol-interferon alpha-2a, pegylated interferon alfa-2a, peginterferon alpha-2a, peg-ifn alpha-2a, peginterferon alfa-2a, pegasys, peg-ifn alfa-2a, peginterferon alpha-2a, pegylated interferon alpha-2a, peginterferon alpha-2a (substance), peg-ifn alpha-2a, peginterferon alfa-2a, peginterferon alfa-2a [chemical/ingredient], peg-ifn alfa-2a
Drug Target(s) [2]:
IFNAR1, IFNAR2
NCIT ID [1]:
C33987
SNOMED ID [1]:
F-C0102

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.